Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-control trial.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin) in this randomized controlled trial publication.

To explore the effect of cotreatment with growth hormone (GH) for ovarian stimulation after pituitary suppression.

Who Took Part

According to the abstract, 18 patients were involved.

PubMed indexes the participants as adults, women only.

Twenty-five IVF patients who had responded suboptimally in a previous treatment cycle.

A subgroup of 18 patients were found to have ultrasound (US) findings of polycystic ovaries (PCO).

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

A randomized, double-blind, placebo-controlled study.

Specialist Reproductive Endocrine and In Vitro Fertilization (IVF) Unit.

What Was Measured

PubMed files the paper under topics including Fertilization in Vitro, Follicular Fluid, Growth Hormone, Insulin-Like Growth Factor I, Menotropins, Ovary and Pituitary Gland.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin) in 18 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1991 (Fertility and sterility), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the HMG (Human Menopausal Gonadotropin) compound page, all human trials.